Background: Acinetobacter baumannii has evolved as a common Multi Drug Resistant (MDR) microbe. This study was conducted to find the profile of antimicrobial resistance and mortality and their associated factors in A. baumannii infection of lower respiratory tract. Materials and Methods: This was a record based cross sectional study done in a tertiary care teaching hospital in Kerala. Records of all the 63, A. baumannii lower respiratory infection in 2017, were retrieved and analyzed. MDR was defined as resistance to at least one agent of three or more antimicrobial classes. Proportion of MDR, carbapenam resistance and resistance to other major antimicrobials were calculated. Determinants of carbapenam resistance and its associated antimicrobial resistance were explored. Proportion of mortality and the associated factors were explored. Student's t-test, chi-square test or fisher exact test were used appropriately. Results: Proportions of MDR and carbapenam resistance were 85.7% and 41.3% respectively. Highest proportion (90.5%) was resistant to piperazillin-tazobactam. Carbapenam resistance was associated with MDR (p-value<0.05). Mean duration of mechanical ventilation and intensive care unit (ICU) stay prior and after the infection were longer for patients with carbapenam resistant strains (p-value<0.05). Mortality rate was 74.6% (95% CI: 63.9% to 85.3%). Older age and ICU stay prior to infection were associated with mortality (pvalue<0.05). Conclusions: Rates of antimicrobial resistance in Acinetobacter baumannii and the mortality were high in the setting, comparable to reports from other parts of India. The drug resistance increases hospital care burden. There is an urgent need to implement stringent infection control measures.
Introduction
The most common and serious Multi Drug Resistance (MDR) pathogens have been encompassed within the acronym "ESKAPE," standing for Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species [1] . Acinetobacter baumannii which has become part of ESKAPE was known to be pan-sensitive in 1970's [2] . This microbe has earned a moniker "Iraqibacter" recently because of the concerns it raised in the conflict zones in Iraq [3] .
Acinetobacter baumannii is a gram-negative, aerobic, pleomorphic, non-motile coccobacillus of low pathogenecity but has become a serious hospital acquired infection worldwide [4] . The organism has diverse mechanisms for antimicrobial resistance and has acquired resistance to almost all commerciallyavailable antibiotics posing significant challenge to the clinician [4] . Another challenging aspect of the microbe is in distinguishing between colonization and true infection, particularly since many infections occur in the setting of colonization [5] .
Data regarding the prognosis of patients with Acinetobacter baumannii infections are limited. This opportunistic pathogen infects immunocompromised individuals, particularly those who have prolonged hospital stay [6] . It was known to be associated with aquatic environments [7] . It colonizes the skin and heavy growth in culture is obtained from the respiratory and oropharyngeal secretions of infected individuals [8] . In recent years, it has been designated as a "red alert" human pathogen due to its extensive antibiotic resistance [9] . Multidrug-resistant (MDR) pathogens have become a cause for serious concern in both nosocomial and community-acquired infections [10] . World Health Organization (WHO) has recently identified antimicrobial resistance as a major threat to public health [11] . In this study, we estimated rates of antimicrobial resistance in Acinetobacter baumannii infection of lower respiratory samples, mortality among the patients affected and associated factors.
Materials and Methods
This was a hospital record based cross sectional study in a tertiary care teaching hospital in south Kerala. The patients were identified from the microbial culture records register, maintained by the department of microbiology. Medical records were retrieved of all the patients whose lower respiratory tract samples, such as bronchoalveolar lavage, mini bronchoalveolar lavage or sputum turned culture positive for Acinetobacter baumannii. The sample size was 63, calculated for an expected prevalence of 88% for MDR, with precision of 8% and α error of 5% [12] . The sample size was achieved by exhaustive sampling over the year 2017.All the positive cultures were tested for antimicrobial susceptibility to ceftazidime, cefepime, gentamicin, amikacin, ciprofloxacin, piperacillin-tazobactam, imipenem, and meropenem. Strains with intermediate susceptibility were considered resistant.
The data collected from medical records were on the antimicrobial resistance, age, gender, hospital setting where the samples were referred, and length of mechanical ventilation before and after Acinetobacter baumannii infection, length of hospital stay and ICU stay after infection, antimicrobial agents administered during hospitalization before Acinetobacter baumannii infection and cause of death. Continuous variables were summarized as mean and standard deviation. Categorical variables were summarized as frequency and percentages. Student's t-test, chi square test or fisher exact test were used appropriately in analysis.
Definitions
Nosocomial lower respiratory infection: At least two of the respiratory signs or symptoms which appear 48 hours after hospitalization among the followingcough, purulent sputum, new infiltrate on chest radiograph consistent with infection [13] . Definitions for the Acinetobacter baumanni antimicrobial resistance used in the study were as follows. Carbapenem-resistance: Resistance to both imipenem and meropenem Carbapenem-sensitive: Sensitive to imipenem or meropenem. Multi Drug Resistance: Resistance to at least one agent of three or more antimicrobial classes [14] .
Results
During the year 2017, total of 63 Acinetobacter baumannii respiratory isolates were obtained in the microbiology department from the hospital. All of them were nosocomial infections. Thirty two cultures showed polymicrobial infections. Most common organism isolated in lower respiratory specimens along with Acinetobacter baumanni infection was ESBL positive Klebsiella pneumoniae. Mean age of the patients was 65.5 years (SD=14.1). The proportion of older persons (age 65 years and above) was 69.8% (n=44).There were 41 (65.1%) males and 22 (34.9%) females. Majority of infections (57, 90.5%) occurred in patients admitted in Intensive Care Units who were also on mechanical ventilation.
The pattern of drug resistance of the Acinetobacter baumannii isolates is depicted in figure 1 . Proportion of carbapenam resistant isolates was (n=26) 41.3%. Proportion of multi drug resistance (MDR) was (n=54) 85.7% (95% CI: 77.1% to 94.3%). The resistance was highest (60, 95.2%) for piperazillin-tazobactum. Carbapenam susceptibility was significantly associated with susceptibility to ceftazidime, cefepime, gentamicin (p-value < 0.05) ( Table 1) . Carbapenam resistance was significant indicator of multi drug resistance (p-value < 0.05) ( Table 1) . Among the carbapenam resistant strains all were MDR, resistant to piperazillintazobactam and resistant to ceftazidime; 96% were resistant to ciprofloxacin and gentamicin; 85% were resistant to amikacin.
Factors affecting carbapenam susceptibility were analyzed and depicted in Table 2 . (Table 3) .
Mortality rate among Acinetobacter baumannii infected patients was 74.6% (95% CI: 63.9% to 85.3%) (n=47). Factors associated with mortality were older age (65 years and above) and ICU stay before infection (p-value<0.05). Multi drug resistance and carbapenam resistance were not associated with mortality (Table 4) .
Discussion
The strength of the study is that the data is from a quality controlled tertiary care microbiology laboratory. The major limitation is that the results may not be generalized since the study was conducted in single center. The study was focused on nosocomial lower respiratory infections due to Acinetobacter baumannii. Among the nosocomial infections, pneumonia is the most common and the organisms are most commonly are gram negative, particularly Acinetobacter baumannii in ICUs [15] . All the Acinetobacter baumannii infections were nosocomial. It has uncanny ability to survive for prolonged periods in hospital environment [16] [17] [18] . The organism commonly targets the most vulnerable hospitalized patients, those who are critically ill with breaches in skin integrity and airway protection [15] . In our study, it was seen that 90% of infections occurred among the patients in ICUs, who were also on mechanical ventilation.
Acinetobacter baumannii are intrinsically resistant to many antibiotics attributed to a slow porin channel mechanism in it [19] . Resistance of Acinetobacter baumannii to carbapenems and antibiotics of other classes varies depending on the country and hospital, but a trend towards increasing resistance to carbapenems is being observed [20, 21] . Exposure to broad-spectrum antibiotics, such as carbapenems, has been identified as a risk factor for acquisition of imipenem-resistant Acinetobacter in studies [9, 20] . Studies have shown that the prior use of carbapenems, third-generation cephalosporins, and/or fluoroquinolonesare risk factor for the acquisition of MDR Acinetobacter baumannii [9, 18] . In our study, carabapenam resistance was seen in 41% of the isolates and all of them were multi drug resistant as well. Prior use of carbapenams was not associated with carbapenam resistance in this study but, the sample size was not powered to find the association. Studies have demonstrated that carbapenem resistant strains can become resistant to all antibiotics [20, 22] . Proportion of multi drug resistance was 85.7% (95% CI: 77.1% to 94.3%) which is comparable to reports from Varanasi in North India (88%) and Nashik in western India (89.4% to 95.9% over four years) [12, 23] . The highest proportion of resistance was to piperacillin-tazobactam (95%) in this study. In a study from Nashik, the proportions of resistant strains to most of the antibiotics were above 77.5% [23] . Longer duration of ICU stay and mechanical ventilation were seen to be factors associated with acquisition of carbapenam resistant strains in our study. This calls for more stringent infection control action plan in the ICUs [11] .
The mortality among Acinetobacter baumannii infected patients was 74.6% (95% CI: 63.9% to 85.3%) in this study. This result is comparable to a study reported from a centre in North India [24] . A study from Korea had reported 30 day mortality rate of 34% which would be regarded as quite low [25] . The differences may be attributed to the ICU facilities and patient profile. Older age and ICU stay were associated with mortality in our study. MDR and carbapenam resistance were not associated with mortality but, the sample size was not powered to find these associations. Many other risk factors for mortality were not studied and multivariate analysis could not be done to adjust for the confounders due to sample size constraints. There are studies which reported higher mortality due to carbapenam resistant strains [26, 27] , but many other studies did not find such an association [27] [28] [29] [30] [31] . Antimicrobial resistance leads to higher health care expenditure [11] . This was reflected in our study as the acquisition of carbapenam resistant strains was associated with longer duration of mechanical ventilation, ICU stay and hospital stay. 
Conclusion
Anti-microbial resistance of Acintobacter baumannii and mortality among the infected patients is high in this tertiary care teaching hospital in Kerala and is comparable to similar study settings in other parts of India. Carbapenam resistance is associated with multi drug resistance. Longer duration of ICU stay and longer duration of mechanical ventilation can lead to acquisition of resistant strains. Resistant strains lead to increased hospital care burden. In the light of the current study, stringent infection control measures are recommended.
